Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933385 | 0.77 | TAAR1 (0.50) | ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL2291118 | 0.74 | ALDH1A1 (0.35) | ALDH1A1TSHRPGK1PGK2CYP11B1 | |
| SCHEMBL5633593 | 0.74 | IDO1 (0.46) | ALDH1A1 | |
| SCHEMBL28591028 | 0.73 | ALDH1A1 (0.56) | ALDH1A1TSHR | |
| SCHEMBL502038 | 0.69 | ALDH1A1 (0.40) | ALDH1A1TSHRPGK1PGK2CYP11B1 | |
| SCHEMBL7536615 | 0.69 | CYP1A2 (0.40) | ALDH1A1TSHR | |
| SCHEMBL467238 | 0.69 | ALDH1A1 (0.50) | ALDH1A1TSHR | |
| SCHEMBL6291666 | 0.68 | TSHR (0.42) | TSHR | |
| SCHEMBL3588189 | 0.67 | IDH1 (0.46) | ALDH1A1TSHRPGK1PGK2CYP11B1 | |
| SCHEMBL3690305 | 0.67 | ALDH1A1 (0.44) | ALDH1A1TSHRPGK1PGK2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112789108-B | Catalyst for asymmetric hydrogenation of compounds containing carbon double bonds | 格拉斯如睦株式会社 | 2023-09-19 | — | — | CN | disclosed |
| EP-3862083-B1 | CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND | GLACEUM INC (KR) | 2023-03-08 | — | — | EP | disclosed |
| US-11420988-B2 | Catalyst for asymmetric hydrogenation of compound containing carbon double bond | GLACEUM, INC. (KR) | 2022-08-23 | — | — | US | disclosed |
| US-20210395282-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND | GLACEUM, INC. (KR) | 2021-12-23 | — | — | US | disclosed |
| EP-3862083-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND | Glaceum, Inc. (KR) | 2021-08-11 | — | — | EP | disclosed |
| CN-112789108-A | Catalyst for asymmetric hydrogenation of compounds containing carbon double bonds | 格拉斯如睦株式会社 | 2021-05-11 | — | — | CN | disclosed |
| WO-2020071818-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND | 주식회사 글라세움 | 2020-04-09 | — | — | WO | disclosed |
| US-20180194775-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-9975904-B2 | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2871179-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011011330-A2 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7268152-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1490317-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003082787-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | ALDH1A1 3249/4885TSHR 67/4885PGK1 4447/4885 |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | ALDH1A1 3156/4885TSHR 64/4885PGK1 4464/4885 |
| US-20180194775-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | ALDH1A1 3249/4885TSHR 67/4885PGK1 4447/4885 |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | ALDH1A1 2659/4885TSHR 452/4885PGK1 449/4885 |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | ALDH1A1 1812/4885TSHR 75/4885PGK1 2048/4885 |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, ACHE | ALDH1A1 465/4885TSHR 4620/4885PGK1 2566/4885 |
| US-20210395282-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND | INF2, DCX, HDHD5 | ALDH1A1 464/4885TSHR 3991/4885PGK1 3967/4885 |
| US-11420988-B2 | Catalyst for asymmetric hydrogenation of compound containing carbon double bond | INF2, DCX, HDHD5 | ALDH1A1 464/4885TSHR 3991/4885PGK1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.